-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi's Subcutaneous Sarclisa Escena Receives FDA Approval To Treat Multiple Myeloma

Benzinga·07/10/2026 12:55:26
Listen to the news

The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across all existing indications of Sarclisa intravenous (IV) formulation. With the approval, Sarclisa Escena is the first anticancer treatment to be administered through both an on-body injector (OBI) and manual SC administration.